<DOC>
	<DOC>NCT02937272</DOC>
	<brief_summary>The main purpose of this study is to evaluate the safety of the study drug known as LY3200882 in participants with solid tumors.</brief_summary>
	<brief_title>A Study of LY3200882 in Participants With Solid Tumors</brief_title>
	<detailed_description />
	<criteria>The participant must have histological or cytological evidence of cancer. Have adequate organ function. Have Eastern Cooperative Oncology Group (ECOG) scale performance status of 0 or 1. Are able to swallow capsules and tablets. Have moderate or severe cardiovascular disease. Have a serious concomitant systemic disorder. Have acute leukemia.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>TGF Beta</keyword>
</DOC>